Future prospective studies investigating the role of c-kit mutations and histologic grade in subcutaneous MCTs for predicting clinical disease progression and risk for metastatic disease and MCT-associated mortality are needed to confirm these hypotheses. The gene discussed is KIT; the disease is metastatic neoplasm.